Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The aging US population
- Dementia world wide
- FDA approved drugs 1996-2007 - the problem
- FDA-approved drugs '96-'11
- The crisis
- Why this failure to find treatments?
- The assumption of drug discovery
- The reality of drug discovery
- Challenges facing the pharma model
- Lab for drug discovery in neurodegeneration
- Permanent staff and collaborators
- High throughput screening equipment
- Imaging instruments for high content analysis
- Medicinal chemistry - balancing properties
- Pipeline - drug discovery projects
- Academia's drug discovery focus
- Advantages of drug discovery in academia
- Disadvantages of drug discovery in academia
- Shared challenges
- Shared resources and approaches
- (Public-private) partnerships
- Multiple sclerosis
- MS is a complex disease
- Previous genetic studies in MS
- International MS genetics consortium (1)
- International MS genetics consortium (2)
- International MS genetics consortium funding
- Publications from the MS consortium
- Collaborative CNS screening initiative
- Duplicated effort
- Industry-academia collaboration: illustration
- A new model for industry-academia collaboration
- The Mass. neuroscience consortium
- From crises, opportunities emerge
Topics Covered
- Increasing numbers of neurological disorders correlates with the growing numbers of elderly
- Paucity of drugs that treat these neurological disorders
- Reasons for this failure
- Need to reassess the traditional division of labor between the for-profit sector and the not-for-profit academic sector
- Transfer of the discovery phase to academia?
- Other aspects of the heretofore-failed neuro drug discovery pipeline e.g. large-scale genetic studies aimed at unearthing new targets
- The need to redefine the precompetitive space
- The need to build new collaborations between companies, and between the commercial and academic sectors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Ivinson, A.J. (2013, March 28). Is there a role for academia in drug discovery [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/ZCFJ1756.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Adrian J. Ivinson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
This is Adrian Ivinson at The
Harvard NeuroDiscovery Center.
And I'm going to be discussing
whether there's a role
for academia in drug discovery.
0:10
But before I start talking
about the role for academia
in drug discovery, let's
quickly review the problems
that we're facing, the
challenge that collectively we
need to address.
What I'm showing here is
a simple graph showing
the part of the US population.
We can see on the vertical
axis, the numbers in millions.
And on the horizontal
axis we can see the year.
Now, if we follow
the blue line, we can
see that back in 1940 there
were only about 10 million
Americans over the age of 65.
But over the next 60, 70 years,
that number gradually rose.
It's a fairly steady
increase up until 2010
when they were just under 40 million
Americans over the age of 65.
But this is the interesting point is
that today, 2012, we're actually at
the inflection point of this curve.
We're seeing a sharp rise
in the number of Americans
exceeding that age such
that over the next 30 years
we're going to more than
double the number of Americans
over the age of 65.
And the lower the line shows
a similar sort of pattern
for those over the age of 85.
Now, the reason I'm pointing
out this increase in the number
of Americans over the age of
65 is that unfortunately
we know that 10% of
that age group suffer
from a neurodegenerative disease.
There are diseases like
Alzheimer's, Parkinson's, ALS,
multiple sclerosis,
and quite a long list
of other rare
neurodegenerative diseases.
So if we're looking at
an aging population where
the number of Americans
over the age of 65
is going to double over
the next few decades,
then we know that the
number of Americans
suffering from neurodegenerative
diseases is also going to double.
And that's a very
significant challenge for us.